Meta Pixel

News and Announcements

Managing Expectations: Overestimating Your Capital Raise in 2 Months vs 2 Years

  • Published July 03, 2023 11:00PM UTC
  • Publisher Wholesale Investor
  • Categories Capital Raising Tips

When it comes to raising capital, many founders find themselves overestimating what can be achieved in a short period of time. The process of raising funds involves various stages, from crafting the offer to preparing the deal room and perfecting the pitch deck. However, the common misconception is that this entire process can be wrapped up in just 2 to 3 months. In reality, this timeline does not hold true for the majority of capital raises.

Experienced founders who have successfully raised capital across multiple companies and rounds understand the importance of giving themselves ample time and space to navigate the capital raising journey. They recognise that rushing through the process can lead to missed opportunities and suboptimal outcomes. In this insightful video, we delve into practical guidance and action steps for developing a well-thought-out capital raising strategy.

YouTube player

By watching this video, you will gain valuable insights on how to manage your expectations, set realistic timelines, and ensure that you allocate sufficient resources for a successful capital raise. Remember, patience and strategic planning are key when it comes to securing funding for your business. Don’t let the allure of a quick capital raise overshadow the importance of thorough preparation and execution.

Equip yourself with the knowledge and strategies necessary to achieve your capital raising goals effectively.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now